Search clinical trials for: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab

Total 544 results

China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
National Cancer Institute (NCI)

Active, not recruiting

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Carcinoid Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2

United States
Bristol-Myers Squibb

Active, not recruiting

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Neoplasms by Site

United States, Australia, Denmark, France, Switzerland, Austria, Canada, Germany, Japan, Netherlands, Norway, Spain, United Kingdom, Finland, Italy
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Renal Cell Carcinoma | Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Solid Tumors

China
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
Hunan Cancer Hospital

Completed

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer... and other conditions

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Sarcoma

China
Symphogen A/S

Active, not recruiting

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Solid Tumor | Metastatic Cancer

United States, Canada, France, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Colorectal Adenocarcinoma | Microsatellite Stable (MSS) Colorectal Adenocarcinomas

United States
Cancer Institute and Hospital, Chinese Academy...
The First Affiliated Hospital with Nanjing Medical University; Fujian Cancer... and other collaborators

Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Esophageal Neoplasms

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
Fred Hutchinson Cancer Center
SignalOne Bio, Inc.

Terminated

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
Northwell Health

Withdrawn

Effective OnabotulinumtoxinA Dose Response Study for Upper Facial Wrinkles

Rhytides
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell... and other conditions

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Renal Cell Carcinoma

Spain, Canada, Portugal, Korea, Republic of, Taiwan, United States, Netherlands, United Kingdom, Czechia, Italy, Finland, Greece, Romania, Australia, Poland, Russian Federation
The Methodist Hospital Research Institute
Pfizer

Recruiting

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE)

Urothelial Carcinoma Bladder

United States
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Not yet recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer

United States
Gregory Daniels

Recruiting

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Melanoma Stage Iv | Renal Cell Carcinoma, Metastatic

United States
Fudan University

Recruiting

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Gastric Cancer

China
Providence Health & Services
Merck Sharp & Dohme LLC; Providence Cancer Center, Earle A. Chiles Research...

Active, not recruiting

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
University of Oxford
Vaccitech (UK) Limited

Unknown

VAccination in Early and ADvanced Prostate caNCEr (ADVANCE)

Castration-resistant Prostate Cancer | Intermediate Risk Prostate Cancer

United Kingdom
Han weidong

Unknown

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Malignancies Multiple

China
Amgen

Active, not recruiting

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

KRAS p.G12C Mutant Advanced Solid Tumors

United States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
Fujian Cancer Hospital

Unknown

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Liang Peng
Guangzhou Virotech Pharmaceutical Co., Ltd.

Unknown

IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

Advanced/Metastatic Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Neoadjuvant Therapy | Locally Advanced Head and Neck Squamous Cell Carcinoma

China
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
Bio-Thera Solutions

Not yet recruiting

BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer

Cervical Cancer

China
Tianjin Medical University Second Hospital
CSPC Pharmaceutical Group Limited

Unknown

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Cancer

China
Hoffmann-La Roche

Completed

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (IMpower133)

Small Cell Lung Carcinoma

Korea, Republic of, United States, Hungary, Poland, China, France, Greece, Spain, United Kingdom, Brazil, Italy, Germany, Mexico, Australia, Serbia, Russian Federation, Japan, Austria, Chile, Czechia, Taiwan
RenJi Hospital
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Recruiting

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

China
Chen Xiaoping

Completed

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Recurrence | HCC

China
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Hepatocellular Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Chuangzhen Chen

Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors (ILDRV1)

Radiotherapy | Immune Checkpoint Blockade | Metastatic Extracranial Malignant Solid Neoplasm | Resistance to Immunotherapy

China
Fudan University

Recruiting

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Cancer of Unknown Primary

China
The Fourth Affiliated Hospital of Zhejiang University...

Recruiting

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Bristol-Myers Squibb

Completed

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Neoplasms by Site

United States
Jason J. Luke, MD
Bristol-Myers Squibb

Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Unresectable Solid Tumors

United States
University of Wisconsin, Madison
Bristol-Myers Squibb; National Cancer Institute (NCI); AnYxis Immuno-Oncology... and other collaborators

Suspended

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Melanoma

United States
Gradalis, Inc.

Completed

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

Melanoma | Malignant Melanoma | Melanoma Recurrent

United States
Fudan University

Unknown

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Fudan University

Unknown

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China

Search clinical trials for: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations